Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials.

CONCLUSION: Tofacitinib has a benefit-risk profile in moderate to severe psoriasis consistent with other systemic treatments. This article is protected by copyright. All rights reserved.
PMID: 30188571 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 6, 2018 Category: Dermatology Authors: Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R Tags: Br J Dermatol Source Type: research